UK approves Kisunla for the treatment of Alzheimer’s disease but NICE …does not pay for it.
SPECIAL REPORT 24.12
On October 23, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the licensing of Eli Lilly’s Donanemab or Kisunla for the treatment of early stage Alzheimer’s disease, but the health technology agency National Institute for Health and Care Excellence (NICE) said
